Goldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $321

Benzinga Newsdesk www.benzinga.com Neutral 54.3%

Neg 0% Neu 54.3% Pos 0%

Goldman Sachs analyst Andrea Newkirk initiates coverage on United Therapeutics (NASDAQ:UTHR) with a Sell rating and announces Price Target of $321.